Skip to content

Advertisement

  • Poster presentation
  • Open Access

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study

  • 1,
  • 1Email author,
  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Retrovirology20107 (Suppl 1) :P63

https://doi.org/10.1186/1742-4690-7-S1-P63

  • Published:

Keywords

  • Atazanavir
  • AIDS Clinical Trial Group
  • Glucose Transporter GLUT4
  • Include Body Mass Index
  • Immunological Failure

Background

Protease inhibitors based antiretroviral therapy has been associated with elevated plasma insulin levels and insulin resistance. HCV infections are an independent risk factor for diabetes development. In vitro Atazanavir (ATV) has shown minimal inhibitory effect on the insulin-regulated glucose transporter GLUT4. Studies in healthy HIV-negative demonstrated a favorable metabolic profile. Clinical studies in HIV and HCV/HIV coinfected pretreated patients with underlying real conditions are needed.

Methods

51 pretreated HIV-1 infected patients who started ATV/r were included prospectively. Insulin resistance was assessed by HOMA (Homeostasis Model Assesment). Hepatotoxicity was defined according to AIDS Clinical Trials Group criteria to ALT values. Clinical data and laboratory parameters were analyzed at baseline and every 12 weeks up to 48. It includes body mass index (BMI), fasting glucose, insulin, triglycerides (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), CD4+ cell count and HIV-1 RNA. HIV monoinfected and HIV/HCV co-infected (pos HCV-RNA) patients were compared.

Results

23 HIV-mono and 28 HIV-HCV coinfected patients were analyzed. Mean age was 40 ± 8 years, male 74%; median CD4 count (IQR) 288 (224-548) cells/μL. 53% plasma HIV-RNA<50 copies/mL. Only 1 case of severe hepatotoxicity (Grade 4) was seen (coinfected patient). Metabolic profile is shown in Table 1. ATV was discontinuated in 4 cases (2 poor adherence and 2 gastrointestinal intolerance). Non virological or immunological failures were documented.

Table 1

 

HCV

BASAL

48-WEEK

Δw48-w0

P(Δw48-w0)

BMI (Kg/m2)

-

24.5 (22-27)

26 (23-29)

0.34 (-1.0-+0.9)

>.05

 

+

22 (20-26)

20 (18-23)

-0.35 (-0.8-+1.2)

>.05

Fasting glucose (mg/dl)

-

87 (83-97)

88 (85-95)

-0.5 (-5.7-+8)

>.05

 

+

94 (83-103)

90 (80-105)

+2 (-24-+12)

>.05

HOMA

-

1 (0.8-3.6)

1.4 (0.9-3.2)

-0.06 (-1.5-+0.8)

>.05

 

+

3.5 (1.8-6.3)

4.5 (3-7.5)

+1.8 (-4.6-+3.1)

>.05

TC (mg/dl)

-

197 (165-215)

179 (161-200)

-18 (-40- -3)

.02

 

+

157 (132-174)

144 (127-165)

-5 (-32-+15)

>.05

TG (mg/dl)

-

149 (122-241)

126 (101-208)

-10 (-92-+17)

>.05

 

+

139 (99-186)

114 (89-197)

0 (-19-+59)

>.05

As Median (Interquartile range). In all comparisons between HCV- vs HCV+ p > .05

Discussion

ATV/r can be safely used in patients with chronic viral hepatitis. ATV/r regimens do not induce insulin resistence and has a good lipid profile in coinfected as in monoinfected patients. These results would be better with unboosted ATV regimens.

Authors’ Affiliations

(1)
HIV Unit, Internal Medicine Service, Universitary Hospital of A Coruña, A Coruña, Spain
(2)
University of A Coruña, A Coruña, Spain

Copyright

© Meijide et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement